Prescient Therapeutics Limited (ASX: PTX)

Company Profile: Prescient Therapeutics Limited (ASX: PTX) is a clinical stage oncology company. It develops novel drugs which are used as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy treatments. The headquarter of the company is situated in South Melbourne, Australia and is being currently headed by Mr. Yatomi-Clarke Steven Lee – the CEO, MD, and Director.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report